Consider alternatives to value-based pricing, says 2020health
Value-based pricing "not in patient interest"
9th May 2013. PMLiVE. “The public have been told that politicians are staying out of the NHS, so this change could seem like hypocritical
interference,” said the report's main author, Barbara Arzymanow, who has spent 25 years as an investment analyst specialising in the pharma industry. Click here.
New drug pricing scheme could politicise decisions and reduce access, says think tank
8th May 2013.British Medical Journal.
346:f2965.Article reporting Barbara's views on value-based drug pricing in the UK.
Barbara Arzymanow, main author of the report said: “The public have been
told that politicians are staying out of the NHS, so this change could seem like hypocritical interference. Patients could mistake value-based pricing for a commitment to make more medicines available, which is not the case. One product can have many uses
and dosage regimes which are of different ‘value’ to different people.
“Pricing of medicines can be improved, but not through this entirely new scheme. The confidence of patients and the
future of medicine are more important than words.” Click here.
UK drug pricing plan could trigger ‘avalanche of problems’
6th May 2013. Article by Andrew Jack in the Financial Times about a think tank report of which Barbara is the main author. Click here.
10th May 2013.The Pharmaceutical Journal.
The independent health think tank report "Value-based pricing: the wrong medicine for the nation?" surveyed public concerns about proposed value-based pricing. Barbara Arzymanow, main author of the report, concluded that "patients could mistake value-based pricing for a commitment to make more medicines available, which is not the case".
The report claims that medicines pricing can be improved and urges the Government to consider alternative solutions, including continuing to allow drug companies to fix prices for individual drugs, lowering the price of older drugs to accommodate high enough prices for new products, developing a pricing system to encourage companies not to overlook rarer diseases in search of drugs for more lucrative markets and encouraging more patient access schemes to help make drugs available on the NHS. Click here
The Delicate Trick
14th December 1991 The New York Times. Article by Philip Crawford
But appearances can be deceiving. "Companies can be quite convincing in presenting a new product as the most advanced and effective in the field," said Barbara Arzymanow of Kleinwort-Benson Securities in London, "but a little research can often reveal a competitor to be several years ahead. You have to be careful not to get drawn in by what corporate officers, or anyone else for that matter, might want you to think." Click here.